![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The purpose of this study was to assess the effects of -866G>A polymorphism of mitochondrial uncoupling protein 2 (UCP-2) on platelet reactivity and prognosis in patients with type 2 diabetes and ischemic stroke (IS). A total of 405 Chinese patients with type 2 diabetes and stroke were assessed in a 4-year follow-up case-control study. Patient response to antiplatelet therapy was measured with the Platelet Function Analyzer-100 by means of collagen/adenosine diphosphate (CADP) and collagen/epinephrine (CEPI) cartridges. The primary end point was a composite of stroke and TIA (transient ischemic attack), the secondary end point was death. The -866G>A polymorphism in UCP-2 was genotyped by TaqMan MGB probe method. The -866G>A SNP in UCP-2 was not significantly associated with recurrence of diabetic ischemical stroke (p = 0.57). A significant trend toward nonfull response to antiplatelet therapy was seen in patients carrying A allel in comparison with those carrying GG genotype, as shown by the CADP and CEPI tests (p < 0.0001). Our 4-year follow-up study shows no association between -866G>A variant of UCP-2 in type 2 diabetes and the risk of developing stroke. But in conclusion, the A allel is associated with clopidogrel resistance.